CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 68	$ 0
Cost of revenues	236	0
Gross loss	(168)	0
Operating expenses:
Research and development	5,920	10,392
General and administrative	14,587	16,835
Acquisition of Exacis in-process research and development	460	0
Impairment of in-process research and development	0	5,990
Total operating expenses	20,967	33,217
Loss from operations	(21,135)	(33,217)
Other expense, net:
Change in fair value of warrant liabilities	215	10,795
Change in fair value of contingent consideration	118	0
Loss on non-controlling investment	(59)	(941)
Interest income	138	0
Interest expense	(614)	(30)
Other expense, net	(334)	(1,141)
Total other (expense) income, net	(536)	8,683
Loss before income taxes	(21,671)	(24,534)
Benefit (provision) for income taxes	3	(45)
Net loss	(21,668)	(24,579)
Series A convertible preferred stock dividend	(16)	(16)
Net loss attributable to common stockholders	$ (21,684)	$ (24,595)
Net loss per common share - basic (in dollars per share)	$ (4.08)	$ (8.06)
Net loss per common share - diluted (in dollars per share)	$ (4.08)	$ (8.06)
Weighted average shares outstanding - basic (in shares)	5,314	3,051
Weighted average shares outstanding - diluted (in shares)	5,314	3,051